An experimental drug that blocks specific calcium channels in immune cells may help interrupt the damaging immune reactions that drive severe viral pneumonia, according to a new study published in The Journal of Clinical Investigation. The drug, called Auxora, targets calcium release-activated calcium (CRAC) channels and appears to dampen harmful interactions between immune cells without suppressing the entire immune system. The findings offer a potential new approach for treating viral pneumonia, though the drug remains in early research stages.

Key takeaways

  • Auxora blocks CRAC channels, which are involved in immune cell signaling.
  • In lab models, the drug reduced harmful interactions between immune cells during viral pneumonia.
  • The study provides new insight into how the drug works, according to the senior author.
  • Researchers caution that further studies are needed before clinical use.

What is Auxora and how does it work?

Auxora is an experimental drug designed to block calcium release-activated calcium (CRAC) channels. These channels sit on the surface of certain immune cells and help control the flow of calcium into the cell. When calcium enters through CRAC channels, it triggers a cascade of signals that can lead to inflammation and immune cell activation. In conditions like severe viral pneumonia, this cascade can become overactive, causing immune cells to attack lung tissue and worsening the infection.

By blocking these channels, Auxora may prevent immune cells from overreacting. Unlike broad immunosuppressants, the drug appears to target only specific circuits within the immune system, potentially preserving the body’s ability to fight the virus while reducing collateral damage.

What the study found

The study, led by researchers at Northwestern University, examined the effects of Auxora in laboratory models of viral pneumonia. According to the senior author, Dr. G. R. Scott Budinger, chief of Pulmonary and Critical Care in the Department of Medicine at Northwestern, the drug helped “disrupt immune circuits” that link different types of immune cells together in a harmful feedback loop. When these circuits are left unchecked, they can amplify inflammation and damage lung tissue.

The authors reported that blocking CRAC channels reduced the activation of key immune cells, including macrophages and neutrophils, which are often implicated in severe pneumonia. This reduction led to less lung injury and improved survival in the animal models used. The study is among the first to show how CRAC channel blockade might specifically affect the cellular interactions that drive viral pneumonia.

Potential implications for treatment

If confirmed in human trials, the approach could represent a step toward precision medicine for pneumonia. Rather than using a one-size-fits-all immune suppression, doctors might one day use drugs like Auxora to target the overactive immune circuits in patients whose pneumonia is driven by an excessive inflammatory response. This could be particularly useful for viral pneumonias, such as those caused by influenza or coronaviruses, where the immune system can cause as much harm as the virus itself.

The findings also open the door to exploring CRAC channel blockers in other inflammatory lung conditions. However, the researchers emphasize that the work is still preclinical, and much more research is needed to determine safety and effectiveness in humans.

Limitations of the study

Because the study was conducted in animal models and laboratory settings, the results cannot be directly applied to human patients. The dosing, timing, and possible side effects of Auxora in humans remain unknown. Additionally, the exact role of CRAC channels in different types of pneumonia may vary, so the drug may not work for every case. The senior author noted that the research provides a “roadmap” for future precision medicine approaches, but that clinical trials are the next necessary step.

Frequently Asked Questions

What is Auxora?

Auxora is an experimental drug that blocks calcium release-activated calcium (CRAC) channels. It is being studied for its ability to calm overactive immune responses in diseases such as viral pneumonia.

How could Auxora help treat viral pneumonia?

By blocking CRAC channels, Auxora may interrupt the harmful interactions between immune cells that can damage lung tissue during severe viral pneumonia. This could reduce inflammation without fully suppressing the immune system.

Is Auxora approved for use in patients?

No, Auxora is not yet approved by the FDA or any other regulatory agency. The recent study was conducted in animal models, and human clinical trials are needed before it can be considered as a treatment.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.